S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
How major US stock indexes fared Friday, 12/8/2023
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
How major US stock indexes fared Friday, 12/8/2023
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
How major US stock indexes fared Friday, 12/8/2023
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
Closing prices for crude oil, gold and other commodities
All the trading advice you’ve ever received boils down to this (Ad)
How major US stock indexes fared Friday, 12/8/2023
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal

TG Therapeutics Stock Price, News & Analysis (NASDAQ:TGTX)

$15.72
-0.31 (-1.93%)
(As of 12/8/2023 ET)
Compare
Today's Range
$15.64
$16.70
50-Day Range
$6.68
$16.45
52-Week Range
$6.46
$35.67
Volume
4.32 million shs
Average Volume
4.42 million shs
Market Capitalization
$2.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.25

TG Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
41.5% Upside
$22.25 Price Target
Short Interest
Bearish
26.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
1.32mentions of TG Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
100.00%
From $0.02 to $0.04 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

249th out of 942 stocks

Pharmaceutical Preparations Industry

92nd out of 448 stocks


TGTX stock logo

About TG Therapeutics Stock (NASDAQ:TGTX)

TG Therapeutics Inc is a biopharmaceutical company that develops and commercializes innovative treatments for multiple sclerosis (MS) and other autoimmune diseases. The company, founded in 2012, is headquartered in New York City and has operations in the United States and Europe. The company aims to provide new and effective therapies to patients with unmet medical needs.

TG Therapeutics has made significant achievements since its inception but has also experienced significant setbacks. The company initially rose to fame by producing the cancer drug Ukoniq which was later pulled from the market due to its ineffectiveness. The company shifted focus and received FDA approvals for a multiple sclerosis drug, Briumvi, for relapsing forms of multiple sclerosis. Additionally, the company conducts extensive clinical trials for other product candidates. These product candidates can potentially provide new treatment options for patients with B-cell malignancies and autoimmune diseases.

TG Therapeutics has a talented and experienced management team dedicated to advancing the company's mission. The current CEO and co-founder of the company is Michael S. Weiss, who has over 25 years of experience in the biopharmaceutical industry. TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. 

TG Therapeutics has seen significant volatility in its stock price over the past few years. In 2021, the stock price increased by over 200% due to positive clinical trial results for its product candidates. However, in 2022, the stock price experienced a sharp decline due to concerns about removing the approved drug Ukoniq from the market, delays in clinical development and increased competition. 

TG Therapeutics operates in the biopharmaceutical industry, characterized by high innovation levels and significant regulatory oversight. The industry is also subject to political and economic pressures, including changes in healthcare policy and pricing pressures from payers.

TG Therapeutics faces competition from other companies developing cancer and autoimmune disease treatments, including large pharmaceutical companies such as Roche and Novartis. However, the company's focus on developing novel therapies for unmet medical needs gives it a competitive advantage.

TG Therapeutics has several growth opportunities in its pipeline. The company is currently developing new product candidates which have the potential to provide new treatment options for patients with MS, B-cell malignancies and autoimmune diseases. Additionally, the company may pursue strategic acquisitions or partnerships to expand its product portfolio and reach new markets.

TG Therapeutics faces risks and challenges that may impact its future growth and success. These include changes in healthcare policy and pricing pressures from payers and increased competition from other companies in the market. Additionally, the company is subject to regulatory oversight and must successfully navigate the clinical development and approval process for its product candidates. Failure to do so may result in delays, increased costs, and potential setbacks for the company.

The company's financial performance is also subject to risks, such as changes in interest rates and the availability of financing. The company's debt levels may limit its ability to invest in research and development. Any significant changes in ownership or management may also disrupt operations and impact the company's growth potential.

Furthermore, the success of TG Therapeutics' product candidates is not guaranteed, and the company may need help demonstrating their safety and efficacy in clinical trials. Failure to obtain regulatory approval for these products or to effectively commercialize them may significantly impact the company's financial performance and market position.

TGTX Stock Price History

TGTX Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
TG Therapeutics: Trying To Fill The Gap Back To $20
TG Therapeutics Inc TGTX
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Why TG Therapeutics Stock Is Crushing It Today
TG Therapeutics Earnings Preview
TG Therapeutics: Things Are Stacking Up Against Briumvi
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
245
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$22.25
High Stock Price Target
$41.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+41.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-198,340,000.00
Pretax Margin
-13.65%

Debt

Sales & Book Value

Annual Sales
$189.77 million
Book Value
$0.40 per share

Miscellaneous

Free Float
137,480,000
Market Cap
$2.38 billion
Optionable
Optionable
Beta
2.30
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report














TGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGTX shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price target for 2024?

8 Wall Street analysts have issued 1 year target prices for TG Therapeutics' shares. Their TGTX share price targets range from $6.00 to $41.00. On average, they expect the company's stock price to reach $22.25 in the next twelve months. This suggests a possible upside of 41.5% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2023?

TG Therapeutics' stock was trading at $11.83 at the beginning of 2023. Since then, TGTX shares have increased by 32.9% and is now trading at $15.72.
View the best growth stocks for 2023 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.44. The biopharmaceutical company had revenue of $165.80 million for the quarter, compared to analysts' expectations of $23.91 million. TG Therapeutics had a negative trailing twelve-month return on equity of 35.58% and a negative net margin of 13.65%. The company's revenue was up 17538.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.26) EPS.

What ETFs hold TG Therapeutics' stock?

ETFs with the largest weight of TG Therapeutics (NASDAQ:TGTX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE).AdvisorShares Let Bob AI Powered Momentum ETF (LETB).

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (2.05%), Schonfeld Strategic Advisors LLC (0.90%), Northern Trust Corp (0.90%), 683 Capital Management LLC (0.89%), Charles Schwab Investment Management Inc. (0.74%) and FMR LLC (0.61%). Insiders that own company stock include Laurence N Charney, Michael S Weiss, Sagar Lonial, Sean A Power and Yann Echelard.
View institutional ownership trends
.

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TGTX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -